Abstract 367MO
Background
There is some evidence that the socioeconomic status (SES) is associated with survival in glioblastoma (GBM), but the findings are limited. We conducted a single centre prospective observational study investigating the association between SES and GBM survival in Italy, where exists a national health service that provides universal coverage.
Methods
This study was a prospective analysis of newly diagnosed GBM patients who underwent chemoradiation between 2018 and 2020 in a hub center for brain cancer research. The SES was measured using the income-brackets, extracted from regional health administrative system. The income-brackets refer to annual gross family income: up to 36,152 euros in income is classified as R1 bracket; between 36,153 and 70,000 euros as R2; between 70,0001 and 100,000 euros as R3; over 100,000 euros as R4.
Results
One hundred six patients were included in the study. In multivariable cox proportional hazard model of survival, a high available income was associated with improved survival HR= 0.623 (95% CI 0.467-0.832; p = 0.001). When adjusted for age, survival remained improved for high-income patients.
Conclusions
We confirm that SES is an important determinant of prognosis in GBM even in the Italian National Health Service which provide universal, largely free and relatively comprehensive healthcare. Despite aspirations to achieve equality in healthcare, socioeconomic differences exist and may impact on clinical outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
365MO - Exploring changes in glioblastoma treatment patterns in Europe and the USA with population-based cancer registry data
Presenter: Francesco Giusti
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
366MO - Incidence of malignant and non-malignant CNS tumours in Hong Kong
Presenter: Ka Man Cheung
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
368MO - Fatty acid synthase inhibitor TVB-2640 with bevacizumab in recurrent glioblastoma
Presenter: William Kelly
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
369MO - Final results of depatuxizumab mafodotin plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO)
Presenter: Marta Padovan
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
370MO - FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
Presenter: Jean-Sebastien Frenel
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
371MO - Usefulness of circulating tumour DNA detection from cerebrospinal fluid in recurrent high-grade glioma
Presenter: Maxime Fontanilles
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
372MO - Melanoma leptomeningeal metastases: A European multicenter cohort
Presenter: Emilie Le Rhun
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
373MO - Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours
Presenter: Andrew Brenner
Session: Mini Oral - CNS
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Matthias Preusser
Session: Mini Oral - CNS
Resources:
Slides
Webcast
Invited Discussant 365MO, 366MO and 367MO
Presenter: Matthias Preusser
Session: Mini Oral - CNS
Resources:
Slides
Webcast